SCHEMBL4064459

SCHEMBL4064459

COc1ccc(-c2cc3ncnc(N(C)c4ccc5c(c4)OCO5)c3s2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
NPC1 O15118 3/20 0.52
RAB9A P51151 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
ALDH1A1 P00352 6/20 0.45
CLK4 Q9HAZ1 5/20 0.45
TSHR P16473 3/20 0.45
CYP1A2 P05177 2/20 0.45
CYP3A4 P08684 2/20 0.45
CYP2D6 P10635 2/20 0.45
MAPK1 P28482 2/20 0.45
CYP2C19 P33261 2/20 0.45
HSD17B10 Q99714 2/20 0.45
LMNA P02545 1/20 0.45
HIF1A Q16665 1/20 0.45
MAP3K8 P41279 1/20 0.45
EGFR P00533 2/20 0.44
HPGD P15428 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930205 0.91 CLK4 (0.45) KMT2ANPC1RAB9ATDP1ALDH1A1
SCHEMBL3938276 0.90 CLK4 (0.51) KMT2ANPC1RAB9ATDP1ALDH1A1
SCHEMBL4066627 0.89 CLK4 (0.47) NPC1RAB9AALDH1A1CLK4TSHR
SCHEMBL4066693 0.88 MAP3K8 (0.46) KMT2ANPC1RAB9ATDP1ALDH1A1
SCHEMBL4064210 0.88 CLK4 (0.47) KMT2ANPC1RAB9ATDP1ALDH1A1
SCHEMBL4069658 0.88 EGFR (0.47) KMT2ANPC1RAB9AALDH1A1CLK4
SCHEMBL4068416 0.88 TYK2 (0.49) NPC1RAB9AALDH1A1CLK4TSHR
SCHEMBL3928353 0.86 EGFR (0.43) NPC1TDP1ALDH1A1CLK4TSHR
SCHEMBL3936367 0.86 CLK4 (0.41) KMT2ANPC1RAB9ATDP1ALDH1A1
SCHEMBL4071470 0.86 CLK4 (0.45) ALDH1A1CLK4TSHRCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 KMT2A 2055/4885NPC1 3333/4885RAB9A 3562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.